Patent · US Active

Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other α-synucleinopathies

US9084832B2 · kind B2 · utility

12Cited by

8References

29Claims

0Family size

Assignee

BioArctic Neruoscience AB · SE

Inventors

Eva Nordström · Vimmerby, SE
Alex Kasrayan · Stockholm, SE
Monica Ekberg · Stockholm, SE
Valentina Screpanti Sundquist · Vilhelmina, SE
Lars Lannfelt · Stockholm, SE
Mats Holmquist · Sollentuna, SE

Key dates

Filing date	Feb 2, 2015
Grant date	Jul 21, 2015
Priority date	—
Expiry date	Feb 2, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/387
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

In an in vivo method for detecting α-synuclein protofibrils in human tissue, an antibody or fragment thereof is administered to a human. The antibody or fragment is labelled with a detectable label. A complex formed between the antibody or fragment and α-synuclein protofibrils in the human tissue is detected. The antibody or fragment has high affinity for human α-synuclein protofibrils and low affinity for α-synuclein monomers and has a combination of three specified variable heavy (VH) CDR sequences and three specified variable light (VL) CDR sequences.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.